Research graph
References from Response of Vestibular Schwannomas in NF2-Related Schwannomatosis (NF2-SWN) to Losartan: A Case Series. Local targets link to admitted publications; unresolved targets remain external evidence.
Neurofibromatosis type 2-related schwannomatosis - an update
10.1016/j.spen.2024.101171 · 2024 · External reference
Clinical and economic burden of neurofibromatosis type 2 in the United States
10.1016/j.clineuro.2020.106053 · 2020 · External reference
The clinical spectrum of paediatric NF2- related schwannomatosis
10.1007/s10689-025-00511-6 · 2025 · External reference
Hearing loss and vestibular schwannoma: new insights into Schwann cells implication
10.1038/s41419-023-06141-z · 2023 · External reference
Neurofibromatosis type 2: hearing preservation and rehabilitation
10.1016/j.neuchi.2018.09.003 · 2018 · External reference
Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2
10.1007/s11060-015-1828-8 · 2015 · External reference
Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence
10.1002/pbc.28228 · 2020 · External reference
The association between age and outcomes of bevacizumab treatment in NF2-related schwannomatosis
10.1097/mao.0000000000004759 · 2026 · External reference
Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma
10.1200/jco.19.01367 · 2019 · External reference
Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models
10.1126/scitranslmed.abd4816 · 2021 · External reference
Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannoma
10.1038/s41467-025-57586-z · 2025 · External reference
Losartan may not prevent vestibular schwannoma growth or related hearing loss during observation
10.1097/mao.0000000000004214 · 2024 · External reference
Angiotensin-receptor blockers prevent vestibular schwannoma–associated hearing loss
10.1097/mao.0000000000004376 · 2025 · External reference
Management of bevacizumab-induced proteinuria using an angiotensin receptor blocker (ARB) in a neurofibromatosis type 2 (NF-2) patient with vestibular schwannoma
2023 · External reference
Hearing in patients with intracanalicular vestibular schwannomas
10.1159/000096152 · 2007 · External reference
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma
10.1093/neuonc/noad066 · 2023 · External reference
Calculating the tumor volume of acoustic neuromas: comparison of ABC/2 formula with planimetry method
10.1016/j.clineuro.2012.12.029 · 2013 · External reference
Calculating the tumor volumes in vestibular schwannomas: are the ABC/2 and volumetric methods comparable?
10.1097/mao.0000000000001423 · 2017 · External reference
Advancing neurofibromatosis and schwannomatosis clinical trial design: consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration
10.1177/17407745231201345 · 2024 · External reference
Lifelines: survival analysis in Python
10.21105/joss.01317 · 2019 · External reference
Matplotlib: a 2D graphics environment
10.1109/mcse.2007.55 · 2007 · External reference
Data structures for statistical computing in Python
10.25080/majora-92bf1922-00a · 2010 · External reference
Array programming with NumPy
10.1038/s41586-020-2649-2 · 2020 · External reference
